USC Norris Comprehensive Cancer Center Opens Newport Beach Radiation Oncology and Imaging Center
USC Norris Comprehensive Cancer Center, part of Keck Medicine of USC, has opened Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging, a state-of-the-art radiation oncology and imaging center, at 4590 MacArthur Blvd. in Newport Beach. The 12,500-square-foot clinical space houses new-to-market imaging and radiation therapy technology in a serene, beach-inspired space designed to help patients feel at ease.
'Our new radiation oncology and imaging center demonstrates our ongoing commitment to providing Orange County with world-class care,' said Rod Hanners, CEO of Keck Medicine. 'We recognize the importance of keeping cancer care close to home and are proud to expand our presence in the community.' The center is equipped with positron emission tomography-computed tomography (PET-CT) imaging and computed tomography (CT) scanners for diagnosis, treatment simulation and monitoring, as well as two state-of-the-art linear accelerators to deliver precision radiation therapy treatment.
Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging will be the first clinical site in Orange County, and just the third in California, to offer SCINTIX biology-guided radiation therapy (BgRT) using the new-to-market RefleXion X1 system.
Unlike other types of radiation therapy that use static images of a patient's anatomy to map treatment areas, BgRT is the first and only radiation therapy delivery modality that uses a PET radiotracer compound that, once injected into the body, interacts with cancer cells to send up-to-the-minute 'signals' about the location of cancer cells, even as the patient breathes or moves slightly. This helps radiation oncologists track, target and treat cancer cells in real time while minimizing damage to healthy cells, which may alleviate some of the side effects of radiation.
BgRT also eliminates the need for placing markers (tiny metal objects positioned inside the patient in or near cancerous tissue to identify where to deliver treatment), as well as enables radiation oncologists to more efficiently treat multiple tumor locations in the same course of therapy.
BgRT recently received breakthrough device designation from the U.S. Food and Drug Administration for treating lung tumors and is currently approved for certain patients with lung and bone tumors.
Keck Medicine will install a second X1 system with BgRT at a medical facility in Pasadena opening later this year. It will be the first university-based academic institution to offer BgRT at multiple locations, bringing new cancer treatment options to the Los Angeles area, Orange County and surrounding communities.
'This groundbreaking technology enables us to provide the best possible care and offer treatment for patients whose options may be very limited,' said May Lin Tao, MD, radiation oncologist and director of clinical operations, regional radiation oncology clinics, with Keck Medicine. Tao is also clinical associate professor of radiation oncology with the Keck School of Medicine of USC. 'We are thrilled to be the first to offer this revolutionary and potentially life-saving treatment to patients in Orange County.'
Keck Medicine of USC - Newport Beach Radiation Oncology and Imaging is less than 15 minutes away from USC Norris' oncology locations in Newport Beach and Irvine, where patients can make appointments with respected medical oncologists who have served Orange County for decades and who treat more medical oncology outpatients in Newport Beach than any other provider.
'This new location expands our spectrum of cancer services in Orange County, ranging from diagnostic imaging to multiple treatment options that optimize outcomes and provide personalized radiation medicine,' said Eric Chang, MD, radiation oncologist with Keck Medicine and chair and professor of radiation oncology with the Keck School.
'The addition of this new location means so much for our patients and their loved ones,' said Louis Vandermolen, MD, medical oncologist with USC Norris Comprehensive Cancer Center, practicing in Newport Beach. 'Our convenient location near our medical oncology offices means that our patients can truly benefit from multidisciplinary, collaborative care from doctors they know and trust.'
Information sourced from Keck Medicine of USC. To learn more, contact mary.ferguson@med.usc.edu.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Yahoo
3 days ago
- Yahoo
Purdue football player provides update on Charles Ross' departure from team
WEST LAFAYETTE ― On Thursday, Purdue football coach Barry Odom announced transfer receiver Charles Ross is no longer with the team. Ross' departure was a health-related issue, Odom elaborated. On Saturday, Ross posted on X that he's retiring from football. "To the fans, Honestly, I'm grateful for everything. God doesn't make mistakes," Ross wrote. "This wasn't my outcome for football. Dreams. Aspirations. Lovers. Fans. Doubters. This is something I cannot control. All the relationships I built from this game, I'm forever grateful. My HEALTH forever comes first. I will be medically retiring from football." Ross transferred to Purdue in January after playing last season at USC. Ross participated in spring football camp and was with the team when fall camp began before being noticeably absent from practice. He was expected to be a contributor offensively. Ross had 70 career receptions for 904 yards and four touchdowns playing for Nevada, San Jose State and USC. Sam King covers sports for the Journal & Courier. Email him at sking@ and follow him on X and Instagram @samueltking. This article originally appeared on Lafayette Journal & Courier: Purdue football receiver Charles Ross retires due to health reasons
Medscape
5 days ago
- Medscape
Restricted Drug Coverage Tied to Higher Risk for MS Relapse
Restricted coverage of medications for relapsing-remitting multiple sclerosis (MS) was associated with a higher risk for relapse, a new study showed. Patients with MS enrolled in Medicare Advantage Prescription Drug plans (MA-PDs) with broader formulary coverage were 8%-12% less likely to experience an MS relapse, while those in broad-coverage stand-alone prescription drug plans (PDPs) had 6%-9% lower odds of relapse. The findings highlight that cost-saving measures used by pharmacy benefit managers to exclude certain drugs from formularies can have tangible negative outcomes, especially for patients with complex or chronic conditions. 'Patients with MS may need to try multiple drugs to find what works best for them. Broad formulary exclusions ultimately undermine the individualized care these patients need,' said lead author Geoffrey Joyce, PhD, director of Health Policy at the Schaeffer Center and chair in the Department of Pharmaceutical and Health Economics at the University of Southern California in Los Angeles, in a news release. The study was published online on August 1 in JAMA Network Open . Cost-Cutting May Come at Patients' Expense Part of the push to exclude certain medications or seek rebates is due to the increasing number of therapies within the same class, the investigators noted. Competition among manufacturers allows pharmacy benefit managers to negotiate better prices via the exclusion of more costly drugs from their formulary. This can prevent some patients from getting their prescribed medication, such as drugs for relapsing-remitting MS, which are not protected by Medicare's Part D classifications. A 2024 study showed that Medicare Part D plan formularies excluded an average 44.7% of brand-only compounds and that drug restrictions for this plan increased over the study period of 2011-2020. To investigate whether such exclusions were associated with relapse episodes for MS patients, the researchers analyzed Medicare data of 50,162 beneficiaries in PDPs (mean age, 58.5 years; 74.9% women; 80.7% White) and 34,708 in MA-PDs (mean age, 58.2 years; 77.2% women; 75.5% White). More MS Therapies, Less Coverage The study timeline was divided into quarters, starting in 2019 (2020 Q2 was left out as a result of COVID-19 disruptions). To gauge patient outcomes, the first four quarters were used as a baseline period and the fifth quarter as the follow-up period. Beneficiary severity of MS was evaluated using the expanded disability status scale derived from the disability/impairment scores. The researchers looked at 15 disease-modifying therapies (DMTs) on the market from 2018 to 2022. In their analysis, the Medicare plans were assumed to cover the five intravenous MS DMTs. The amount of on-formulary MS DMTs was calculated to give a four-quarter moving average and DMTs were classified as on formulary if their generic name was covered by the plans. Plans were deemed low coverage if the four-quarter moving average of DMTs was below the plan's median during baseline. For the follow-up portion, logistic regression models were employed for MS relapse episodes, and Poisson or negative binomial regression models were used for nonbinary dependent variables such as the number of relapse episodes. Multivariable regression models were used to control for patient characteristics. PDPs typically covered only four of the 15 drugs across four classes, while MA-PDs covered double this across five classes. Many oral and injectable DMTs were frequently not covered by plans particularly in stand-alone plans, such as teriflunomide (amount of plans without compound on formulary: PDP, 87.7%; MA-DP, 43.3%), ofatumumab (PDP, 99.6%; MA-DP, 86%), and interferon beta-1a (PDP, 86.5%; MA-DP, 41.4%). The rate of any MS relapse was higher for low-coverage plans compared with broader coverage plans for PDPs (10.6% vs 9.5%; odds ratio [OR], 0.88 [95% CI, 0.85-0.91]) and MA-PDs (7.8% vs 6.9%; OR, 0.88 [95% CI, 0.84-0.92]). MS is most commonly diagnosed between 20 and 40 years of age — a limitation of the study was that most Medicare beneficiaries are older than this cohort. Other limitations were potential administration errors inherent in health claims data and that quarterly periods might not be sufficient to fully evaluate the relationship between formulary coverage and relapse episodes. The researchers noted that the effect of such restrictions might be exacerbated for Part D beneficiaries, thanks to the new $2000 annual cap on out-of-pocket drug expenses. 'Innovative new treatments have made it possible to slow or prevent symptoms for some of the most complex diseases, but costs remain a challenge,' Joyce said. 'We must find sustainable ways to ensure all patients can access these potentially life-changing treatments.'
Business Wire
7 days ago
- Business Wire
High Schoolers Inspired by Health Care Professionals: Leadership Conference Held at CHLA Spotlights Potential Career Paths
LOS ANGELES--(BUSINESS WIRE)--More than 130 high school students and their families took part in the third annual High School Healthcare and Leadership Conference at Children's Hospital Los Angeles (CHLA). This year, the conference hosted 9th through 12th grade students from over 20 different L.A.-area high schools, more than double the number of schools represented at last year's event. Children's Hospital Los Angeles is educating the next generation of health care professionals, including a recent conference for high schoolers on medical field career opportunities. Share 'Here, today, you are all welcome, and we want to encourage you to pursue your dreams,' said CHLA Orthopedist Bianca Edison, MD, MS, FAAP, addressing a room of students and their parents during the conference. CHLA's Department of Surgery organized the Aug. 2 nd event in collaboration with the University of Southern California (USC) McMorrow Neighborhood Academic Initiative (NAI) and USC's Medical Counseling, Organizing and Recruiting (MedCOR) program. The conference was designed to inspire and encourage L.A. youth who are interested in health care careers. Throughout the day, health care industry speakers, including 50 CHLA staff and faculty members, led presentations and activities to promote career and leadership opportunities among the students. The staff involved ranged from anesthesiologists, neonatologists, and surgeons to financial advisors, quality and clinical effectiveness leaders, and clinical dieticians. Video editors: See this link for b roll of conference The students were eager to take part in these opportunities. 'Working in pediatrics was always a dream for me, and to be able to learn from actual pediatricians and connect with other students is amazing,' said Canise, an incoming senior in high school. 'My uncle had skin cancer, and seeing health care professionals doing everything they could to help him was inspiring. That's where the spark started for me.' The conference also involved informational sessions for parents, focusing on how they can support their children's career aspirations. Denise Weibel, whose daughter attended the conference, is also a Registered Nurse in CHLA's Steven & Alexandra Cohen Foundation Newborn and Infant Critical Care Unit (NICCU). 'My daughter has an interest in health care, but other than her mom being a nurse, she didn't know about all the different roles there are,' Weibel said. 'Most people think about a doctor or a nurse, but there is so much more that you can do.' Dr. Edison, an attending physician in the hospital's Jackie and Gene Autry Orthopedic Center, facilitated the event, working with Senior Project Manager Josue Arvayza and Administrative Assistant Corina Recinos. Dr. Edison led an opening keynote address with Rolando Gomez, MBA, Director of Community Relations and Strategic Initiatives at CHLA. 'New voices in health care will share new ideas in terms of how to help families, how to connect with others, and more,' Gomez said. Dr. Edison agreed. 'Health innovation is the next frontier in this field, and that frontier is in your hands,' she said to the students. After the opening address, the students split into groups to rotate through various sessions. Students toured an operating room and learned about the team members involved in surgery, led by Ambulatory Surgical Center Manager Katherine Perez. They also attended career and networking panel discussions, led by faculty and staff members such as Pediatrician Fasha Liley, MD, Senior Vice President and Surgeon-in-Chief Mark Krieger, MD, Neonatologist Kameelah Gateau, MD, MS, Physical Medicine and Rehabilitation Resident Eric Poole, MD, and Orthopedic Surgeon Tyler Tetreault, MD. There were also workshops in which students learned how to intubate, or insert a breathing tube into the mouth, suture a wound, and perform CPR. In one workshop, they were taught how to tie tourniquets to control bleeding, earning a Stop the Bleed certification from the American College of Surgeons. Another incoming senior, Anaiah, spoke about the different potential pathways the conference presented. 'I saw my mom's mom go through breast cancer, and I always wanted to be in the medical field,' Anaiah explained. 'It was really eye-opening to see how many different ways there are to enter this field and all the different majors people had in college before entering health care.' Later in the day, the conference ended with a closing keynote address led by Nina Lightdale-Miric, MD, Director of the Hand and Upper Extremity Orthopedic Program at CHLA, and 3D Printing Program Lead and Simulation Technician Satchel Clendenin. Clendenin left conference attendees with a positive message. 'Build your community and always act with kindness and empathy.' Video link here: About Children's Hospital Los Angeles Children's Hospital Los Angeles is at the forefront of pediatric medicine and is the largest provider of hospital care for children in California. Since its founding in 1901, CHLA has delivered a level of pediatric care that is among the best in the world. Ranked one of the top 10 children's hospitals in the nation by U.S. News & World Report, Children's Hospital Los Angeles provides comprehensive and compassionate care to one of the largest and most diverse pediatric patient populations in the country. The hospital is the top-ranked children's hospital in California and the Pacific U.S. region for 2024-25. A leader in pediatric research, CHLA is among the top 10 children's hospitals for research funding from the National Institutes of Health. The Saban Research Institute of Children's Hospital Los Angeles supports the full continuum of research, translating scientific discoveries into life-changing treatments for patients around the globe. As a pediatric academic medical center, CHLA is also home to one of the largest graduate education programs for pediatricians in the United States. The hospital's commitment to building stronger, healthier communities is evident in CHLA's efforts to enhance health education and literacy, introduce more people to careers in health care, and fight food insecurity. To learn more, follow CHLA on Facebook, Instagram, LinkedIn, YouTube, and X, and visit
